NRIX insider filing: 20,000 RSUs granted to Chief Scientific Officer

Rhea-AI Filing Summary

Nurix Therapeutics (NRIX) filed a Form 4 reporting an equity grant to its Chief Scientific Officer. On 10/14/2025, the reporting person received 20,000 restricted stock units (RSUs), each representing a right to receive one share of Nurix common stock.

The RSUs were reported at a price of $0 for the derivative security and are held as direct ownership. The award will vest on the second anniversary of the date of grant, contingent on continuous service through that date, after which shares will be delivered. RSUs do not have an expiration date; they either vest or are canceled prior to vesting.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hansen Gwenn

(Last) (First) (Middle)

C/O NURIX THERAPEUTICS, INC.

1700 OWENS STREET, SUITE 205

(Street)

SAN FRANCISCO CA 94158

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nurix Therapeutics, Inc. [ NRIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0(1)	10/14/2025		A		20,000		(2)	(3)	Common Stock	20,000	$0	20,000	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

2. The RSUs will vest on the second anniversary of the date of grant, subject to the Reporting Person's continuous services to the Issuer from the date of grant through such vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

3. RSUs do not expire; they either vest or are canceled prior to the vest date.

Remarks:

	/s/ Daniel Burbach, as Attorney-in-Fact for Gwenn Hansen	10/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Nurix (NRIX) disclose in this Form 4?

A grant of 20,000 RSUs to the Chief Scientific Officer on 10/14/2025.

How many RSUs were granted and what does each represent?

The award is 20,000 RSUs, and each RSU represents one share of common stock.

What is the vesting schedule for the NRIX RSUs?

The RSUs will vest on the second anniversary of the date of grant, subject to continuous service through that date.

Is there an exercise price or cost for these RSUs?

The filing lists a price of $0 for the derivative security; RSUs deliver shares upon vesting.

Do the NRIX RSUs expire?

RSUs do not expire; they either vest or are canceled prior to vesting.

How is ownership reported after the transaction?

The 20,000 derivative securities are shown as direct (D) ownership following the transaction.

Who is the reporting person’s role at Nurix?

The reporting person is an Officer, serving as Chief Scientific Officer.